The Role of Radiation Therapy in Oligometastasis to Lung and Liver Metastasis
Keywords:
radiation therapy, stereotactic body radiation therapy, oligometastasisAbstract
Some 60%–70% of cancer patients suffer metastasis. Oligometastasis refers to metastatic disease with limited volume usually five or fewer metastatic lesions. Curative use of surgical metastasectomy has been based on non-randomized evidence, especially for isolated lung and liver metastases, with phase III randomized control trials limited to select sites, such as surgical resection plus radiotherapy (RT) for solitary brain metastases compared with RT alone. Stereotactic Body Radiation Therapy (SBRT) is a highly conformal RT modality delivered at high doses per fraction; it has been shown to be safe in treating oligometastases. Although randomized studies for SBRT in oligometastases are limited, a recently published phase II study showed significant improvement in progression-free survival with local consolidative therapy after initial systemic therapy in patients with colorectal carcinoma and non-small cell lung carcinoma. Several ongoing randomized phase III studies are evaluating the use of SBRT in oligometastatic disease. Early detection and aggressive local treatment, such as surgery or RT, can improve progression-free and overall survival without increased complications for cancer patients with oligometastases.are summarized.
Downloads
References
Department of Medical Services. Cancer; Thailand Medical Services Profile 2011-2014 First Edition. Ministry of Public Health: Department of Medical Services; 2014. https://www.hiso.or.th/hiso/picture/reportHealth/report/report8_6.pdf.
National Cancer Institute. Cancer Registry Unit NCIT, Cancer in Thailand 2018.; 2018.
National Cancer Institute, Department of Medical Services. National cancer control programmes (พ.ศ. 2556-2560). Nonthaburi: National Cancer Institute, Department of Medical Services; 2013.
Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10(1):S2. doi:10.1186/bcr1988
Otake S, Goto T. Stereotactic Radiotherapy for Oligometastasis. Cancers. 2019;11(2). doi:10.3390/cancers11020133
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8-10. doi:10.1200/JCO.1995.13.1.8
Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878-886. doi:10.1016/j.ijrobp.2011.08.036
Palma DA, Salama JK, Lo SS, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549-557. doi:10.1038/nrclinonc.2014.96
Niibe Y, Hayakawa K. Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy. Jpn J Clin Oncol. 2010;40(2):107-111. doi:10.1093/jjco/hyp167
Ning MS, Gomez DR, Heymach JV, Swisher SG. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. Transl Lung Cancer Res. 2019;8(1):97-106. doi:10.21037/tlcr.2018.09.21
Rabassa L, Maria L. Oligometastatic cancer: A curable disease stage. Rep Pract Oncol Radiother. 2013;18:S25-S26. doi:10.1016/j.rpor.2013.04.011
Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. The Lancet. 2004;363(9422):1665-1672. doi:10.1016/S0140-6736(04)16250-8
Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619-2626. doi:10.1093/annonc/mds053
Ruers T, Van Coevorden F, Punt CJA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. JNCI J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx015
Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682. doi:10.1016/S1470-2045(16)30532-0
Gomez D, Tang C, Zhang J, et al. Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558-1565. doi:10.1200/JCO.19.00201
Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4(1):e173501-e173501. doi:10.1001/jamaoncol.2017.3501
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet. 2019;393(10185):2051-2058. doi:10.1016/S0140-6736(18)32487-5
Benson AB III, VAA-HM. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2019. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Published 2019.
Folprecht G, Grothey A, Alberts S, Raab H-R, Köhne C-H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol Off J Eur Soc Med Oncol. 2005;16(8):1311-1319. doi:10.1093/annonc/mdi246
van der Pool AEM, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377-382. doi:10.1002/bjs.6895
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1572-1578. doi:10.1200/JCO.2008.19.6329
Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081-1087. doi:10.1245/s10434-010-1405-5
Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol Stockh Swed. 2006;45(7):838-847. doi:10.1080/02841860600904821
Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys. 2011;81(3):e39-47. doi:10.1016/j.ijrobp.2010.12.047
Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol WJG. 2014;20(15):4220-4229. doi:10.3748/wjg.v20.i15.4220
Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007;84(1):203-210. doi:10.1016/j.athoracsur.2007.03.028
De Giacomo T, Rendina EA, Venuta F, Ciccone AM, Coloni GF. Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. Chest. 1999;115(5):1441-1443. doi:10.1378/chest.115.5.1441
Welter S, Theegarten D, Trarbach T, Maletzki F, Stamatis G, Tötsch M. Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry. J Thorac Cardiovasc Surg. 2011;141(5):1218-1222. doi:10.1016/j.jtcvs.2010.08.089
Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72(2):398-403. doi:10.1016/j.ijrobp.2008.01.002
Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74(1):47-54. doi:10.1016/j.ijrobp.2008.06.1939
Ernst-Stecken A, Lambrecht U, Mueller R, Sauer R, Grabenbauer G. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2006;182(12):696-702. doi:10.1007/s00066-006-1577-x
Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJM, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;107(3):409-413. doi:10.1016/j.radonc.2013.05.024
Downloads
Published
How to Cite
Issue
Section
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของราชวิทยาลัยจุฬาภรณ์
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับราชวิทยาลัยจุฬาภรณ์ และคณาจารย์ท่านอื่น ในราชวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใด ๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
